Literature DB >> 22734599

Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis.

Jun Iwamoto1, Kaori Yago, Yoshihiro Sato, Hideo Matsumoto.   

Abstract

We report on the case of a severely osteoporotic elderly Japanese woman with bisphosphonate-associated osteonecrosis of the jaw (ONJ), who was treated successfully with teriparatide. A 79-year-old woman with severe osteoporosis and bisphosphonate-associated ONJ was treated with teriparatide after debridement of the necrotic tissue in the jaw bone. Computed tomography (CT) images revealed the bone defect in the mandible after debridement of the necrotic tissue associated with ONJ. According to the attending dentist, the ONJ healed after 2 months of therapy. After 3 months of treatment, a robust increase in the serum level of the bone formation marker, serum intact procollagen type 1 N-terminal propeptide, was noted and a repeat CT revealed improvement of the bone defect of the mandible. These results suggest the beneficial effects of teriparatide therapy in the severely osteoporotic elderly woman with ONJ.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22734599     DOI: 10.1007/bf03261908

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  25 in total

1.  Diagnostic criteria for primary osteoporosis: year 2000 revision.

Authors:  H Orimo; Y Hayashi; M Fukunaga; T Sone; S Fujiwara; M Shiraki; K Kushida; S Miyamoto; S Soen; J Nishimura; Y Oh-Hashi; T Hosoi; I Gorai; H Tanaka; T Igai; H Kishimoto
Journal:  J Bone Miner Metab       Date:  2001       Impact factor: 2.626

2.  PINP as an aid for monitoring patients treated with teriparatide.

Authors:  Mika Tsujimoto; Peiqi Chen; Akimitsu Miyauchi; Hideaki Sowa; John H Krege
Journal:  Bone       Date:  2010-12-17       Impact factor: 4.398

3.  Sunlight exposure is important for preventing hip fractures in patients with Alzheimer's disease, Parkinson's disease, or stroke.

Authors:  J Iwamoto; T Takeda; H Matsumoto
Journal:  Acta Neurol Scand       Date:  2011-06-18       Impact factor: 3.209

4.  Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in hospitalized, elderly women with Alzheimer's disease: a randomized controlled trial.

Authors:  Yoshihiro Sato; Jun Iwamoto; Tomohiro Kanoko; Kei Satoh
Journal:  J Bone Miner Res       Date:  2005-04-04       Impact factor: 6.741

Review 5.  Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

Authors:  Anthony B Hodsman; Douglas C Bauer; David W Dempster; Larry Dian; David A Hanley; Steven T Harris; David L Kendler; Michael R McClung; Paul D Miller; Wojciech P Olszynski; Eric Orwoll; Chui Kin Yuen
Journal:  Endocr Rev       Date:  2005-03-15       Impact factor: 19.871

6.  Teriparatide and osseous regeneration in the oral cavity.

Authors:  Jill D Bashutski; Robert M Eber; Janet S Kinney; Erika Benavides; Samopriyo Maitra; Thomas M Braun; William V Giannobile; Laurie K McCauley
Journal:  N Engl J Med       Date:  2010-10-16       Impact factor: 91.245

7.  A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).

Authors:  M Shiraki; M Fukunaga; K Kushida; H Kishimoto; Y Taketani; H Minaguchi; T Inoue; R Morita; H Morii; K Yamamoto; Y Ohashi; H Orimo
Journal:  Osteoporos Int       Date:  2003-04-10       Impact factor: 4.507

8.  Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in stroke patients.

Authors:  Yoshihiro Sato; Norifumi Metoki; Jun Iwamoto; Kei Satoh
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

9.  Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

Authors:  Robert Lindsay; Wim H Scheele; Robert Neer; Gerhardt Pohl; Silvano Adami; Carlos Mautalen; Jean-Yves Reginster; Jan J Stepan; Stephen L Myers; Bruce H Mitlak
Journal:  Arch Intern Med       Date:  2004-10-11

10.  Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency.

Authors:  Bess Dawson-Hughes; Peiqi Chen; John H Krege
Journal:  J Clin Endocrinol Metab       Date:  2007-10-02       Impact factor: 5.958

View more
  8 in total

Review 1.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Authors:  A Khan; A Morrison; A Cheung; W Hashem; J Compston
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

Review 2.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

Review 3.  A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.

Authors:  J F Chen; K H Yang; Z L Zhang; H C Chang; Y Chen; H Sowa; S Gürbüz
Journal:  Osteoporos Int       Date:  2014-08-20       Impact factor: 4.507

4.  Strontium ranelate improves delayed healing of osteolytic lesions of the jaw in a man with chronic osteomyelitis. Case report.

Authors:  Konstantinos D Stathopoulos; Efthymia Giannitsioti; Archondoula N Fragkou; Aristides B Zoubos; Panagiotis J Papaggelopoulos; Grigoris Skarantavos
Journal:  Clin Cases Miner Bone Metab       Date:  2014-01

5.  [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].

Authors:  B Svejda; Ch Muschitz; R Gruber; Ch Brandtner; Ch Svejda; R W Gasser; G Santler; H P Dimai
Journal:  Wien Med Wochenschr       Date:  2016-02

6.  Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients.

Authors:  Akira Matsuo; Hayato Hamada; Hidetoshi Takahashi; Ayako Okamoto; Hiroshi Kaise; Daichi Chikazu
Journal:  Odontology       Date:  2015-05-09       Impact factor: 2.634

Review 7.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

Review 8.  Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ).

Authors:  Yong-Dae Kwon; Deog-Yoon Kim
Journal:  Dent J (Basel)       Date:  2016-11-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.